Pharmacokinetic-guided Dosing of Emicizumab
Conditions
Hemophilia A With Inhibitor · Hemophilia A Without Inhibitor · Hemophilia A, Severe · Adolescent · Child · Adult
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
Saskia Schols, Dr, MD (Sub-investigator)Maastricht University Medical Center, Maastricht, Limburg, Netherlands
Floor Moenen, Dr, MD (Sub-investigator)Amsterdam University Medical Center, Amsterdam, North Holland, Netherlands
Contact: Study coordinator (Michiel Coppens, Dr, MD) · m.coppens@amsterdamumc.nl · +31(0)20 566 5964Michiel Coppens, Dr, MD (Sub-investigator)Leids Universitair Medisch Centrum, Leiden, South Holland, Netherlands
Paul den Exter, Dr, MD (Sub-investigator)Erasmus University Medical Center, Rotterdam, South Holland, Netherlands
Marjon Cnossen, Dr. MD (Sub-investigator)HagaZiekenhuis, The Hague, South Holland, Netherlands
Paula Ypma, MD (Sub-investigator)University Medical Center Groningen, Groningen, Netherlands
Louise Hooimeijer, MD (Sub-investigator)University Medical Center Utrecht, Utrecht, Netherlands
Contact: Principal Investigator (Kathelijn Fischer, Dr, MD)Konrad van der Zwet, MD (Sub-investigator)Lize F.D. van Vulpen, Dr, MD (Sub-investigator)Roger E.G. Schutgens, Prof, MD (Sub-investigator)Paul van der Valk, MD (Sub-investigator)Karin P.M. van Galen, Dr, MD (Sub-investigator)Nanda Uitslager, Msc (Sub-investigator)
Study leads
Study Officials Fischer, Dr, MD
Principal Investigator
UMC Utrecht